Skip to main content
. Author manuscript; available in PMC: 2007 Aug 6.
Published in final edited form as: J Vasc Surg. 2007 Jun;45(6S):33–38. doi: 10.1016/j.jvs.2007.02.069

Table 2.

Clinical trials on the effectiveness of the β3 integrin antagonists in the inhibition of restenosis in the coronary arteries.

Study Antagonist against β3 integrin Type of injury TLR Reference
EPIC ReoPro αvβ3, αIIbβ3 Angioplasty, atherectomy Reduced 49
Lincoff et al. ReoPro αvβ3, αIIbβ3 Stenting Reduced 30
IMPACT II Integrilin αIIbβ3 Angioplasty No difference 31
ERASER ReoPro αvβ3, αIIbβ3 Stenting No difference 32
CAPTURE ReoPro αvβ3, αIIbβ3 Angioplasty No difference 50

TLR (targeted lesion revascularization).